Chemical Property of 3-Chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-5 H-dibenzazepine HCl
Chemical Property:
- Appearance/Colour:off-white solid
- Vapor Pressure:9.63E-08mmHg at 25°C
- Melting Point:189-190 °C
- Boiling Point:434.2 °C at 760 mmHg
- Flash Point:216.4 °C
- PSA：6.48000
- LogP:5.39540
- Storage Temp.:Store at RT
- Solubility.:H2O: 25 mg/mL
- Hydrogen Bond Donor Count:1
- Hydrogen Bond Acceptor Count:3
- Rotatable Bond Count:4
- Exact Mass:350.1316542
- Heavy Atom Count:23
- Complexity:346
- Purity/Quality:
-
99%, *data from raw suppliers
Clomipramine hydrochloride *data from reagent suppliers
Safty Information:
- Pictogram(s):
Xn
- Hazard Codes:Xn,T,F
- Statements:
20/21/22-39/23/24/25-23/24/25-11-36/37/38
- Safety Statements:
36-45-36/37-16-7-62-38-36/37/39-28-26-24/25-22-20/21-13
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:[H+].CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.[Cl-]
-
Description
Clomipramine is a tricyclic antidepressant, the 3-chlorinated derivative of imipramine . Like imipramine, clomipramine potently inhibits serotonin and norepinephrine reuptake (Kis = 7.4 and 96 nM, respectively). It also is an antagonist at histamine, muscarinic acetylcholine, α1-adrenergic, and dopamine receptors (Kds = 31, 37, 38, and 190 nM for H1, M1, α1, and D2, respectively).
-
Uses
Potent, selective 5-HT uptake blocker Serotonin reuptake inhibitor. Antidepressant; antiobsessional agent anti-depressant, serotonin uptake inhibitor
-
Therapeutic Function
Antidepressant
-
Clinical Use
#N/A
-
Drug interactions
Potentially hazardous interactions with other drugs
Alcohol: increased sedative effect.
Analgesics: increased risk of CNS toxicity with
tramadol; possibly increased risk of side effects with
nefopam; possibly increased sedative effects with
opioids.
Anti-arrhythmics: increased risk of ventricular
arrhythmias with amiodarone - avoid; increased
risk of ventricular arrhythmias with disopyramide,
flecainide or propafenone; avoid with dronedarone.
Antibacterials: increased risk of ventricular
arrhythmias with delamanid and moxifloxacin and
possibly telithromycin - avoid with delamanid and
moxifloxacin.
Anticoagulants: may alter anticoagulant effect of
coumarins.
Antidepressants: possibly increased serotonergic
effects with duloxetine; enhanced CNS excitation
and hypertension with MAOIs and moclobemide;
concentration possibly increased with SSRIs; risk
of ventricular arrhythmias with citalopram and
escitalopram - avoid; possible increased risk of
convulsions with vortioxetine.
Antiepileptics: convulsive threshold lowered;
concentration reduced by carbamazepine,
phenobarbital and possibly fosphenytoin, phenytoin
and primidone.
Antimalarials: avoid with artemether/lumefantrine
and piperaquine with artenimol.
Antipsychotics: increased risk of ventricular
arrhythmias especially with droperidol, fluphenazine,
haloperidol, pimozide, sulpiride and zuclopenthixol
- avoid; increased risk of ventricular arrhythmias
with risperidone; increased antimuscarinic effects
with clozapine and phenothiazines; concentration
increased by antipsychotics.Antivirals: increased risk of ventricular arrhythmias
with saquinavir - avoid; concentration possibly
increased with ritonavir.
Atomoxetine: increased risk of ventricular
arrhythmias and possibly convulsions.
Beta-blockers: increased risk of ventricular
arrhythmias with sotalol.
Clonidine: tricyclics antagonise hypotensive
effect; increased risk of hypertension on clonidine
withdrawal.
Cytotoxics: increased risk of ventricular arrhythmias
with arsenic trioxide.
Dapoxetine: possibly increased risk of serotonergic
effects - avoid.
Dopaminergics: avoid use with entacapone; CNS
toxicity reported with selegiline and rasagiline.
Methylthioninium: risk of CNS toxicity - avoid if
possible.
